- Allergy vaccines, also known as allergen immunotherapy, are increasingly recognized as essential components in the long-term management of allergic conditions such as hay fever, asthma, and insect sting allergies, due to their ability to modify the disease course and provide sustained relief by desensitizing the immune system to specific allergens
- The growing demand for allergy vaccines is primarily driven by the global rise in allergy prevalence, increased awareness of immunotherapy's long-term benefits, and the limitations of conventional symptomatic treatments
- North America dominated the allergy vaccine market with the largest revenue share of 41.7% in 2024, supported by a high burden of allergic diseases, increasing adoption of advanced immunotherapies, and strong healthcare expenditure, with the U.S. leading in clinical research, approvals, and availability of allergy vaccine formulations across diverse patient groups
- Asia-Pacific is expected to be the fastest growing region in the allergy vaccine market during the forecast period due to rising urban pollution, improved access to healthcare, and growing awareness of allergic diseases and their treatments
- Subcutaneous immunotherapy (SCIT) segment dominated the allergy vaccine market with a market share of 48.1 % in 2024, driven by its proven efficacy, long-lasting immune tolerance, and widespread use in treating allergic rhinitis and allergic asthma
